News | January 26, 2015

American Society of Clinical Oncology Recognizes Gensignia's Research in Lung Cancer Screening

New diagnostic blood test plus low-dose CT reduces false-positive rate

Gensignia, lung cancer, LDCT, microRNA, ASCO

Image courtesy of Gensignia Life Sciences.

January 26, 2015 — Research by Gensignia’s scientific co-founders has been recognized in Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology published online in the Journal of Clinical Oncology (JCO) on Jan. 20, 2015.

The ASCO report states: "Additional recent research will help improve the efficacy of low-dose CT [computed tomography] lung cancer screening and reduce potential harms by identifying the populations that stand to benefit the most from screening, and developing ways to reduce false-positive screening results."

"A recent study addressed the problem of false-positive findings by developing a new diagnostic blood test for lung cancer (this study was funded in part by a grant from the NIH). The experimental test is noninvasive; it only requires a blood sample, rather than a potentially painful and risky biopsy. By analyzing molecules called microRNA in a patient's blood, physicians can determine if the abnormality detected on a scan is truly lung cancer. In a large validation study, combination of the microRNA test and low-dose CT resulted in a five-fold reduction of false-positive screening rates (from 19.4 percent to 3.7 percent)."

Gensignia's scientific co-founders, Gabriella Sozzi, Ph.D.; Mattia Boeri, Ph.D.; and Ugo Pastorino, M.D., are attributed with the discovery that the evaluation of certain microRNAs in the blood of subjects at high risk for lung cancer (heavy smokers) can be used to determine, with improved accuracy, the likelihood that lung cancer is developing or has already developed. The discovery was made in the context of screening high risk subjects using routine low-dose computed tomography (LDCT) scans for the presence of potentially cancerous lung masses. Their research was published in the Proceedings of the National Academy of Sciences (PNAS) in 2011.

The microRNA assay was further validated in a large clinical study completed in 2013 and its results published in JCO in January 2014. This clinical validation was a correlative study from the Multicenter Italian Lung Detection (MILD) Trial that was published in the European Journal of Cancer Prevention in 2012. The authors concluded from the results of the clinical validation study that the MSC Lung Cancer assay had predictive, diagnostic and prognostic value and reduced the high false-positive rate of LDCT, thus potentially improving the efficacy of lung cancer screening.

For more information: www.gensignia.com

Related Content

Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | Computed Tomography (CT) | August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
The American Lung Association created LUNG FORCE, a national movement to defeat lung cancer
News | Lung Cancer | August 02, 2017
To raise public awareness of lung cancer—the leading cancer killer of men and women—the American Lung Association's...
GE’s DoseWatch is a digital informatics solution that automatically collects, monitors and reports on radiation dose indices for diagnostic imaging exams
News | Radiation Dose Management | July 31, 2017
GE Healthcare announced that it has licensed computed tomography (CT) organ dosimetry technology developed at Duke...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
New York Hospital Finds Significant Cost Savings With Toshiba’s Aquilion One CT
News | Computed Tomography (CT) | July 25, 2017
In five years, Kaleida Health’s Stroke Care Center (SCC) at the Gates Vascular Institute in Buffalo, N.Y., has realized...
Samsung Introduces FDA-Cleared BodyTom Elite CT Scanner
Technology | Computed Tomography (CT) | July 24, 2017
Samsung announced U.S. Food and Drug Administration (FDA) approval of the BodyTom Elite, an upgraded version of its...
Sponsored Content | Videos | CT Angiography (CTA) | July 21, 2017
DAIC and ITN Editor Dave Fornell discusses some of the most innovative new computed tomography (CT) technology and tr
ACR Updates Radiation Oncology and Medical Physics Guidance With ASTRO and AAPM
News | Radiation Dose Management | July 19, 2017
July 19, 2017 — The American College of Radiology (ACR) recently collaborated with professional medical societies to
Sponsored Content | Videos | CT Angiography (CTA) | July 19, 2017
Matthew Budoff, M.D., FACC, professor of medicine, David Geffen School of Medicine at UCLA, endowed chair of preventi
Overlay Init